Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS

Conclusions PK profile, α4-integrin saturation, lymphocyte counts, and safety observed in these pediatric patients are comparable to those reported in adults. Classification of evidence This study provides Class I evidence that natalizumab PK/PD parameters and safety profile are similar in adults and pediatric patients in the short term. Longer studies, also including a larger number of younger subjects (aged 10–12 years), are required to further inform about long-term PK and PD parameters in pediatric patients with MS.

http://nn.neurology.org/cgi/content/short/6/5/e591?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - June 30, 2019 Category: Neurology Authors: Ghezzi, A., Comi, G., Grimaldi, L. M., Moiola, L., Pozzilli, C., Fantaccini, S., Gallo, P. Tags: All Pediatric, Patient safety, Multiple sclerosis Article Source Type: research